Home
About
Overview
Sharing Data
ORCID
Help
History (1)
The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer.
Hurwitz MD. The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer. Transl Androl Urol. 2019 Jul; 8(Suppl 3):S303-S306.
View in:
PubMed
authors with profiles
Mark Hurwitz